Here is Ørnskov’s new job
After US giant AbbVie’s acquisition of Shire, Flemming Ørnskov will no longer be in charge of the Ireland-based outfit. But he can look forward to a sizeable compensation.
by Benjamin Werner Christensen
US drug group AbbVie has finally acquired it’s Irish rival Shire for USD 54 billion, meaning Danish CEO Flemming Ørnskov will no longer be the top chief of a major pharmaceutical corporation. But he will play a crucial role in the future of the new AbbVie, it is revealed in a 43 pages announcement released by Shire in connection with the acquisition agreement.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Ørnskov: Here are the next breakthroughs
For abonnenter
